12 Health Care Stocks Moving In Friday's After-Market Session

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

12 Health Care Stocks Moving In Tuesday's After-Market Session

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease